HPV and the New Velocity Clinical Research HPV Vaccine Clinical Trial

HPV Overview

With over 100 known variants and no known cure, the human papillomavirus (HPV) infects the skin or moist areas of the body, resulting in warts, unusual growths or sores. Most HPV cases lead to mild infections, but some can cause cervical and other cancers in both women and men. HPV is very common, infecting more than 3 million people annually in the United States. In fact, 40 percent of Americans will contract HPV, which is transmitted through direct contact and can last several days or even weeks.

HPV Causes, Complications and Prevention

HPV can be contracted genitally through sexual activity and oral sex with an infected individual can result in upper respiratory lesions. However, HPV can also pass through cuts or abrasions on the skin, simply by touching HPV warts or infected surfaces. Contributing HPV contraction factors include age, multiple sexual partners and weakened immune systems.

HPV can sometimes go away on its own, but when it doesn’t, it can lead to a blocked vaginal canal which may cause delivery complications for pregnant women; and if left untreated for a prolonged period, HPV can also lead to cervical cancer, as well as cancers of the vagina, penis or anus.

HPV is usually preventable by a vaccine, but it is also recommended to wear shoes in public restrooms, use condoms during sex and refrain from sex with multiple partners.

HPV Diagnosis

Diagnosis of HPV requires an examination and lab testing or imaging. Common tests for HPV include a vinegar/acetic solution which will turn the infected area white, as well as a genetic test for DNA analysis to check for high risk variants of HPV which can cause cancer. In women, a pap smear may also be used for testing.

HPV Treatment

Although not curable, HPV is treatable by a physician. Anti-tumor medications may be administered directly to warts or warts may be removed by freezing with liquid nitrogen (cryotherapy); burning with an electrical current; or removing with laser surgery. HPV vaccination is recommended to prevent further infections.

Velocity Clinical Research

The mission, at Velocity Clinical Research, is to help make the world a better place with a future filled with hope and extraordinary medical possibilities. Through vigilant monitoring and testing, the Velocity Clinical Research study team consistently helps develop vital medical interventions that often result in effective treatments and improved quality of life for both our clinical trial volunteers and the greater community as a whole.

Velocity Clinical Research clinical trial participants often have access to innovative medications and therapies well before they become available to the general public through commercial markets. Clinical study volunteers are also able to take a more active part in their own healthcare. In addition, Velocity Clinical Research volunteers are paid for their time, there are no costs for the medical procedures or treatments provided and there is no insurance necessary to participate.

The Velocity Clinical Research doctors and experienced research personnel work one-on-one with clinical trial volunteers to monitor and assess the benefits and effectiveness of certain treatments. Velocity Clinical Research can support up to 26 in-house patients and a large number of outpatients. The Velocity Clinical Research facility is conveniently located at 1410 S. Ridgewood Avenue in Edgewater, Florida.

If you would like to play an integral role in enhancing medical evaluation and care, as well as take advantage of the personal benefits of becoming a Velocity Clinical Research volunteer, you are invited to enroll with Velocity Clinical Research so that you can be contacted about studies conducted in your area. Simply access the patient portal on our website at riversideclinicalresearch.com. You can also reach Velocity Clinical Research by email at info@velocityclinical.com.  

The Velocity Clinical Research HPV Clinical Study

In the battle against HPV, clinical research is crucial, as it has been estimated that, in some countries, more than 99 percent of cervical cancers can be prevented. Velocity Clinical Research is currently conducting HPV clinical research trials.

Clinical research studies need to include a variety of different types of people, as certain conditions, treatments and preventions may affect people differently based on their age, gender, ethnicity, medical condition and medical history. The specific research study currently being conducted by Velocity Clinical Research will compare an investigational vaccine with a previously approved vaccine across a certain age group of women.

Join us in our investigational study to determine whether a particular HPV study vaccine is safe and will help the body produce antibodies that can effectively combat the different variants of HPV. If you are a woman, between the ages of 16 and 26, who has not been previously vaccinated against HPV, and you would like to learn more, please contact the professional research team at Velocity Clinical Research by calling 386-428-7730 from 8 a.m. to 4:30 p.m. Monday through Friday for more information or to see if you are a qualified candidate.

If you decide to help Velocity Clinical Research work toward medical advancements to improve our world through HPV vaccine research, and the Velocity Clinical Research team determines that you are eligible for study participation, you will receive a total of three injections (of either the investigational vaccine or an HPV vaccine which has already been approved) in your arm over the course of six months. The entire clinical trial will last approximately 12 months.